Ranganathan Ram
Psychiatry · Wilmington, DENPI 1003846163
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $163,321 of the $201,840 with a category attached, or 80.9%. Otsuka America Pharmaceutical, Inc. accounts for 81.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $140,428 and has fallen 100.0% since, to $18 in 2025. Among psychiatry clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 509 payments — averaging $396.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$165K
- Johnson & Johnson$35K
- Bausch Health US, LLC$591
- Otsuka Pharmaceutical Development & Commercialization, Inc.$329
- Sunovion Pharmaceuticals Inc.$317
- Lundbeck LLC$210
- plus $1K from 15 others
What the payments were for
- Consulting fees$1,2961%
- Speaking & faculty fees$163,32181%
- Travel & lodging$29,97715%
- Food & beverage$7,2424%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 319 | $164,776 |
| Johnson & Johnson | 57 | $34,562 |
| Bausch Health US, LLC | 52 | $591 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $329 |
| Sunovion Pharmaceuticals Inc. | 16 | $317 |
| Lundbeck LLC | 13 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $149 |
| Axsome Therapeutics, Inc. | 2 | $128 |
| Alkermes, Inc. | 1 | $120 |
| Jazz Pharmaceuticals Inc. | 5 | $87 |
| Neos Therapeutics, LP | 5 | $86 |
| Vanda Pharmaceuticals Inc. | 5 | $76 |
| Adlon Therapeutics L.p. | 4 | $72 |
| AbbVie(2 entities) | 4 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $64 |
| Merck | 4 | $62 |
| Ironshore Pharmaceuticals Inc. | 3 | $59 |
| Eisai Inc. | 2 | $42 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$113,161
- ABILIFY MAINTENA$49,073
- SPRAVATO$33,861
- ARISTADA$480
- ARISTADA INITIO$120
- Auvelity$110
How this compares
$201,840 in reported general payments places this provider in the 95th percentile of 114 psychiatry providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 11 | $15,230 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,175 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $1,708 |
| Duloxetine Hcl | 59 | $1,266 |
| Alprazolam | 112 | $858 |
| Bupropion XlBupropion Hcl | 53 | $813 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 23 | $752 |
| Escitalopram Oxalate | 43 | $747 |
| Lamotrigine | 38 | $523 |
| Clonazepam | 35 | $384 |
| Aripiprazole | 15 | $382 |
| Lorazepam | 22 | $373 |
| Alprazolam ErAlprazolam | 14 | $343 |
| Imipramine Hcl | 12 | $247 |
| Lurasidone Hcl | 11 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $164,776 | $15,23011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $149 | $6,17513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 114 psychiatry providers in Delaware.
Other psychiatry in Wilmington
- Manisha WadhwaWilmington$89K
- Vishesh AgarwalWilmington$46K
- Kathlyn RowenWilmington$5K
- Sandeep GuptaWilmington$4K
- Nana BerikashviliWilmington$3K
- Karl McIntoshWilmington$2K
- Fawzia HasanWilmington$2K
- Jose CapiroWilmington$1K
- Imran TrimziWilmington$1K
- Chandrakala KathiravanWilmington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.